Advertisement

Topics

Summit Therapeutics presents poster on Phase Out DMD clinical trial

08:22 EDT 14 Mar 2018 | Proactive Investors

The recently announced positive interim data from PhaseOut DMD showed that after 24 weeks of treatment, there was a significant and meaningful reduction in muscle damage, as well as a significant reduction in muscle inflammation, in patients treated with ezutromid

Original Article: Summit Therapeutics presents poster on Phase Out DMD clinical trial

NEXT ARTICLE

More From BioPortfolio on "Summit Therapeutics presents poster on Phase Out DMD clinical trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...